Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by 683 Capital Management LLC

683 Capital Management LLC grew its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 5.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 630,000 shares of the biopharmaceutical company’s stock after buying an additional 30,000 shares during the quarter. 683 Capital Management LLC’s holdings in Sage Therapeutics were worth $3,421,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Picton Mahoney Asset Management increased its holdings in Sage Therapeutics by 126.0% during the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 3,581 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Sage Therapeutics during the fourth quarter worth approximately $49,000. Ieq Capital LLC purchased a new stake in shares of Sage Therapeutics during the fourth quarter worth approximately $57,000. US Bancorp DE raised its holdings in Sage Therapeutics by 22.3% in the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 2,268 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in Sage Therapeutics by 21.6% in the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 2,446 shares during the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Analyst Ratings Changes

SAGE has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a research report on Friday, April 25th. Scotiabank cut their price target on Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research note on Wednesday, February 12th. Piper Sandler lowered their price objective on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. Wedbush reiterated a “neutral” rating and issued a $6.00 price objective on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, HC Wainwright restated a “neutral” rating and set a $12.00 target price (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $8.81.

Sage Therapeutics Price Performance

Sage Therapeutics stock opened at $7.48 on Friday. The business has a 50 day simple moving average of $7.54 and a 200-day simple moving average of $6.78. Sage Therapeutics, Inc. has a 12 month low of $4.62 and a 12 month high of $14.31. The stock has a market capitalization of $459.88 million, a PE ratio of -1.14 and a beta of 0.48.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.02). The firm had revenue of $14.06 million during the quarter, compared to analyst estimates of $14.12 million. Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The firm’s revenue was up 78.0% on a year-over-year basis. During the same quarter last year, the business posted ($1.80) EPS. As a group, equities research analysts anticipate that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.